Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II

Recruiting now · Phase 3

Conditions studied: Cardiac Surgery, Vasoplegia

In brief

The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate/severe acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate/severe AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.

Key facts

Study ID
NCT06615102
Run by
Universität Münster
People needed
1022
Starts
2025-03-31
Expected to finish
2027-04-01
Last updated by the study team
2025-07-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.